The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...

CARsgen Therapeutics reports positive Phase II data for satri-cel in advanced gastric and GEJ cancers, meeting the primary ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...

China-based biotech Duality Biologics (DualityBio) yesterday revealed that Sino-American BeiGene has exercised its exclusive ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving ...

China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal ...

The UK's MHRA warns against purchasing weight-loss drugs without a prescription due to health risks, amid a global rise in ...

Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...

India's Parliamentary panel has come down heavily on the National Pharmaceutical Pricing Authority (NPPA) and directed it to ...